Press Releases

 
Press Releases
Date Title and Summary View
Feb 20, 2018 SALT LAKE CITY, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that the National Comprehensive Cancer Network (NCCN) has updated its medical guidelines for prostate cancer treatment to broadly include biomarker testing in prostate cancer. The changes to the guidelines include new language supporting Pro...
Feb 15, 2018 SALT LAKE CITY, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage breast cancer has been published in JAMA Oncology.  A key finding is that Myriad's EndoPredict...
Feb 7, 2018 SALT LAKE CITY, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, annou...
Feb 6, 2018 Total Revenues of $194.0 Million GAAP Diluted EPS of $0.45 and Adjusted EPS of $0.31 Up 19 PercentCompany Raises Financial Guidance for Fiscal Year 2018 SALT LAKE CITY, Feb. 06, 2018 (GLOBE NEWSWIRE) -- My...
Jan 25, 2018 SALT LAKE CITY, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal second-quarter 2018 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, February 6, 2018.  During the call, Mark C. Capone, president and CEO and Bryan Riggsbee...
Jan 22, 2018 SALT LAKE CITY, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that the company is applauding a new consensus statement from a team of international experts with screening recommendations on hereditary prostate cancer that was published in ...
Jan 12, 2018 SALT LAKE CITY, Jan. 12, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) approved BRACAnalysis CDx® for use as a companion diagnostic by healthcare professionals to identify patients with HER2-negat...
Jan 3, 2018 SALT LAKE CITY, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that AstraZeneca will use the Company's myChoice® HRD Plus in an exploratory analysis to identify women with advanced ovarian cancer who may benefit f...
Dec 19, 2017 SALT LAKE CITY, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine,  announced today that Mark C. Capone, president and CEO, is scheduled to present at the JP Morgan Annual Healthcare Conference at 2:00 p.m. PT on January 8, 2018, in San Francisco...
Dec 12, 2017 SALT LAKE CITY, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today...
Page:
1
... NextLast
= add release to Briefcase